SMTISanara MedTech Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~23% a year FCF growth. Roughly in line with its three-year revenue growth of 23% a year.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SMTI's price assumes
Sanara MedTech Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.46× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.4%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +23%
Growth the price implies · The price pays for +23% free cash flow growth a year for a decade; revenue has grown +23% a year over the last three.
- Price / book
- 22.4
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 22.4
- EV / EBITas of 2026-Q1
- 22.8
- EV / salesas of 2026-Q1
- 1.79
- Free cash flow, trailing twelve months
- $4.5M
- Market capitalisation
- $321M
- 3-year revenue growth
- +23%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #13 of 21 by RyuScore